Author of

• 13707

  +

  P1.06 - Poster Session/ Screening and Early Detection (ID 218)

  • Event: WCLC 2015
  • Type: Poster
  • Track: Screening and Early Detection
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/07/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)

  • 13727

    +

    P1.06-020 - Detection of Aberrant ALK Expression from Circulating Tumor Cells for Accurate Monitoring of ALK Driven NSCLC (ID 3277)

    09:30 - 09:30  |  Author(s): L.W. Abad
    • Abstract
    • Slides

    Background:
    Insight Genetics Inc. and Biocept, Inc. have established a collaboration to develop a non-invasive work flow to enhance detection of the oncogenic Anaplastic Lymphoma Kinase (ALK) status in NSCLC patients. A barrier to detection of oncogenic transcripts in circulating tumor cells (CTCs) has been purification methods that are incompatible with downstream qPCR detection technologies. In contrast, Biocept's proprietary CTC capture technology has been shown to be benign for follow up qPCR detection using Insight Genetics proprietary qPCR-based oncogenic ALK detection assay.
    
    Methods:
    Initial studies were conducted to demonstrate cell capture on the Biocept platform with spiked ALK fusion positive H3122 cells. These studies show this to be a feasible option for non-invasive detection of ALK mRNA. A pre-amplification allele-specific approach including reference controls was incorporated. H3122 cells spiked into peripheral blood also demonstrated feasibility of the accurate detection of aberrant ALK expression using the Biocept CTC extraction methodology and Insight Genetics’ qPCR detection strategy.
    
    Results:
    Results from these studies and the detection of aberrant ALK expression from a cohort of ALK positive patients will be presented along with the potential to use CTCs to monitor ALK inhibitor resistant mutation profiles.
    
    Conclusion:
    Together, Biocept’s proprietary CTC capture technology coupled to Insight Genetics qPCR ALK detection assay appears to be a viable strategy to accurately monitor ALK status in NSCLC patient populations using a liquid biopsy.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.